---
title: "CollPlant Biotechnologies Updates on Patent, AbbVie Payment, and Cost Reductions"
date: "2025-02-12 19:45:04"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioCollplant Holdings ( (CLGN) ) just..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2170812299-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

Collplant Holdings ( [(CLGN)](https://www.tipranks.com/stocks/clgn) ) just unveiled an announcement.

CollPlant announced it has been granted a new U.S. patent for its photocurable dermal filler technology, strengthening its intellectual property in the U.S. market. The company also reported an achievement of a $2 million contingent payment from AbbVie tied to its rhCollagen technology. Additionally, CollPlant is implementing cost reduction measures, including a 20% workforce cut, to extend its cash runway and focus on advancing its product pipeline in 2025, notably its regenerative breast implant product toward clinical trials.

**More about Collplant Holdings**

CollPlant Biotechnologies is a regenerative and aesthetic medicine company specializing in 3D bioprinting of tissues and organs, as well as medical aesthetics. Its products are based on plant-derived recombinant human collagen (rhCollagen), targeting applications in tissue repair, aesthetics, and organ manufacturing. The company has a significant market focus, particularly in the dermal filler segment through a strategic partnership with AbbVie.

**YTD Price Performance:** -6.56%

**Average Trading Volume:** 10,853

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** $40.66M

For detailed information about CLGN stock, go to [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/clgn/stock-analysis).

Trending Articles:
------------------

* [Meta Stock Alert! Wins New Street-High Price Target from Tigress Financial](https://www.tipranks.com/news/meta-stock-alert-wins-new-street-high-price-target-from-tigress-financial)
* [Buffett’s Berkshire Ups Occidental Stake to 28.3% by Buying More Shares](https://www.tipranks.com/news/buffetts-berkshire-ups-occidental-stake-to-28-3-by-buying-more-shares)
* [Here’s One Reason to Hold GameStop Stock, Says Top Investor](https://www.tipranks.com/news/heres-one-reason-to-hold-gamestop-stock-says-top-investor)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/collplant-biotechnologies-updates-on-patent-abbvie-payment-and-cost-reductions)
